Thyroid hormone receptors (TRs) are members of the ligand-inducible transcription factor superfamily. The two major functional TRs (a1 and b1) have different spatial and temporal expression patterns and specific physiological functions for these isoforms are now starting to emerge. By expressing these TR isoforms individually in Swiss 3T3 fibroblasts, we found that TRb1 expression, in the absence of hormone, provokes a proliferation arrest in G0/G1, lengthening the cycling time. Upon serum stimulation TRb1-expressing cells showed a marked delay in the induction of cyclins D and E, in the phosphorylation of retinoblastoma protein, and in the activation of cyclindependent kinase 2, accompanied by increased levels of cyclin-dependent kinase inhibitor p27 Kip1 . Accordingly, serum-stimulated E2F-1 transcriptional activity was repressed by TRb1 in transient transfection experiments. Analysis of the receptor domains required for this effect confirmed that there is no need for a functional ligandbinding domain while the DNA-binding domain is essential. In this work, we demonstrate for the first time that TRb1 participates in the molecular mechanisms that control cell proliferation. The unliganded TRb1 impairs the normal induction of the G1/S cycle regulators preventing progression into the S phase.
Introduction
Thyroid hormone nuclear receptors (TRs) belong to the superfamily of ligand-inducible transcription factors, which includes receptors for steroids, retinoic acid and vitamin D3. TRs are encoded by two genes (a and b) that give rise to several isoforms through different promoters and alternative splicing (Koenig et al., 1989; Chassande et al., 1997) . The major functional receptors TRa1 and b1 exhibit distinct spatial and temporal expression during development (Forrest et al., 1990; Strait et al., 1990) , and genetic ablation of each gene renders strikingly different phenotypes in mice, suggesting isoform-specific functions. Unliganded TRs bind to DNA and are able to regulate transcription (Hashimoto et al., 2001) . Indeed, abnormal regulation of transcription by unliganded TRs is thought to explain the reason why hypothyroidism results in more severe defects in postnatal development of central nervous system than does the inactivation of all TRs in knock-out mice (O'Shea and Williams, 2002; Flamant and Samarut, 2003) .
In recent years, many studies have analysed alterations in the expression of TR genes in different types of human neoplasias. Both gross chromosomal and minor mutations have been found as well as changes in their level of expression (for a review see Gonzalez-Sancho et al., 2003) . The role that these modifications have in tumor generation or progression is still unclear. The major control over proliferation and cell cycle is carried out by cyclins, cyclin-dependent kinases (Cdks), Cdk inhibitors (Ckis), the retinoblastoma susceptibility protein (Rb), and the E2F family of transcription factors. The primary regulators of G1 progression are the D-type cyclins in association with the regulatory partner Cdk4/6, and cyclin E in association with Cdk2. However, the key molecule in this pathway and in commitment to S-phase entry is Rb. Hypophosphorylated Rb binds to E2F transcription factors, blocking their activity. Rb phosphorylation frees the E2F complexes, allowing them to transactivate their target genes, which are required for cell-cycle progression and entry of the cell into S phase (Sherr et al., 1994; Herwig and Strauss, 1997) .
Thyroid hormone (triiodothyronine, T 3 ) influences a variety of physiological processes, including initiation of metamorphosis in amphibians (Brown et al., 1995) , metabolism in mammals, and development of the vertebrate nervous system (Oppenheimer and Schwartz, 1997) . In many cell types, like erythrocytes (Bauer et al., 1998) , myocytes , B-lymphocytes (Paavonen, 1982) , and nerve cells, such as oligodendrocytes and neural cells (Lebel et al., 1994; Billon et al., 2001) , T 3 induces differentiation, a process that is linked to proliferation arrest and exit of the cell cycle. From these reports there is not a clear correlation between the effects on cell proliferation and the type of TR isoform being expressed in the different models. Even more, almost nothing is known with regard to the possible role of the receptors on cell proliferation in the absence of ligand. To address the question whether the major TRs affect cell growth, and to gain insight into the distinct physiological functions displayed by these two isoforms, we have expressed TRa1 and TRb1 separately in Swiss 3T3 fibroblasts, a cell system widely used for proliferation studies (Rozengurt and Sinnett-Smith, 1983) . Our results indicate that TR expression attenuates the growth of serum-stimulated fibroblasts, with a striking effect of the b1 isoform. TRb1-expressing cells have reduced levels and activity of key G1/S cycle regulators. These include downregulation of D-type cyclins and Cdk2 activity, upregulation of p27 Kip1 , and hypophosphorylation of Rb. Supporting these findings, we also show that serum-stimulated E2F-1 transcriptional activity is repressed by transient expression of TRb. The TRb1 growth arrest is observed in the absence of ligand, and accordingly, a ligand-binding domain mutant of TRb1 is able to mediate the same E2F-1 transcriptional inhibition as the wild type, meanwhile an intact DNAbinding domain is required. Thus, this is the first report showing that unliganded TRb1 provokes a proliferation arrest by targeting the key molecular regulators of the cell cycle.
Results

Stable expression of TRa1 and TRb1 isoforms in mouse Swiss 3T3 fibroblasts
Swiss 3T3 fibroblasts were infected with the retroviral expression vector pBabe, or its derivatives containing cTRa1 or hTRb1 cDNAs. After infection, the expression of each receptor isoform was determined by RT-PCR in these cells (Figure 1a) . Then, several clones were isolated after puromycin selection. The level of expression of functional receptors was assessed in a quantitative manner by performing binding assays with radiolabeled T 3 (Table 1) . Cells infected with the control vector (pBabe) displayed the same very low T 3 binding as noninfected (parental) cells. The clones selected for use in subsequent experiments were as follows: for the a1 isoform, TR12a and TR10a, with 4.9-and 3.6-fold increased binding, respectively, and for the b1 isoform, TR8b and TR6b, with 5.3-and 2.3-fold increased binding, respectively. TR protein expression in these clones was also confirmed by Western blot (Figure 1b) .
Expression of unliganded TRb1 impairs fibroblast proliferation
To investigate whether the expression of each receptor isoform affects fibroblast proliferation, we performed [ 3 H]thymidine incorporation assays in cells growing asynchronically (Figure 2a ) using the clones presenting the highest content of functional receptors: TR12a, and TR8b, along with pBabe cells as a control. Strikingly, Figure 1 Expression of TRa1 and TRb1 in retrovirally infected Swiss 3T3 cells. (a) Expression of TRa1 and TRb1 genes was analysed by RT-PCR in Swiss 3T3 fibroblasts retrovirally infected with control vector (pBabe), or derived vectors expressing chick TRa1 (TRa), and human TRb1 (TRb). Specific primers for each TR isoform were used to amplify cDNA obtained from the different cell types. TRa and TRb cells specifically expressed the retrovirally delivered isoform, whereas the pBabe cells did not show any amplified band. Negative controls were performed in the absence of cDNA (À). (b) Western blot analysis of TRa1 and TRb1 proteins in those infected Swiss 3T3 clones that showed the highest T 3 binding capacity (TR10a, TR12a TR6b, TR8b) ]thymidine incorporation as the control cells. The addition of thyroid hormone did not modify the growth capabilities of any of these cell types (data not shown). Given the importance of the observed effects produced by unliganded TRb1 on cell proliferation, we decided to characterize the mechanisms of this inhibition. First, we designed an experiment to fully exclude possible effects of clonal variation. Using the two clones for each isoform that displayed the highest content in functional receptors (see Table 1 ), we estimated the cell number in culture. As shown, in both clones expressing TRb1, cell proliferation was blocked (Figure 2b ). Clone TR8b exhibited the most severe effect after 7 days in culture (B50% growth inhibition), whereas clone TR6b showed a more modest effect (B40% growth inhibition). On the contrary, similar levels of expressed functional TRa1 had no significant effect on fibroblast growth (Figure 2c ). Then, we analysed by flow cytometry the percentage of cells in the different phases of the cell cycle. In pooled TRb1 fibroblasts, we found a significant (Po0.05) increase (B15%) of cells in G0/G1 and a concomitant decrease (B20%) of cells in S phase compared to pooled pBabe and TRa fibroblasts (Figure 3 ).
Cell cycle is lengthened in TRb1-expressing fibroblasts
To examine whether the expression of TRb1 had any effects upon cell-cycle duration, we established its length by a cumulative 5-bromo-2 0 -deoxyuridine (BrdU) labeling assay. As shown in Figure 4 and described under 'Materials and methods', the cumulative labeling index was determined, and total cell-cycle time was calculated for control (pBabe) and TRb cells (clone 8). We found that cell-cycle duration in control cells (30 h) was different of cells expressing TRb1, in which it was 10 h longer (40 h). Altogether, the results obtained so far indicate that expression of TRb1 provokes an accumulation of fibroblasts in G0/G1 accompanied by a delay in S-phase entrance.
Expression of TRb1 provokes a marked delay in the molecular changes governing the G1/S transition Since phosphorylation of the Rb protein is a key event in the G1/S transition, we first examined whether Rb phosphorylation status was altered by the expression of TRb1. For this purpose, pBabe and TR8b fibroblasts were rendered quiescent and triggered to enter a new cycling round by serum stimulation. Cell extracts were obtained at the indicated times, and phosphorylation of Rb was analysed by Western blot (Figure 5a ). In quiescent cells (G0), Rb was hypophosphorylated (Rb) both in pBabe and TR8b cells. The hyperphosphorylated form of Rb (Rb pp ) was clearly detectable in control cells 16 h after serum stimulation. In contrast, TR8b 4 cells/ml) in T 3 /T 4 -depleted medium. Cell number was determined by Crystal Violet staining at indicated times as described in 'Materials and methods'. Expression of the TRb1 isoform impaired Swiss 3T3 proliferation, whereas the expression of TRa1 showed no significant effect. Results are the mean7s.e. values of three independent experiments performed in duplicate Figure 3 Cell-cycle distribution of the TRb1-and TRa1-expressing cells. Cell-cycle phase distribution was analysed by flow cytometry. Pooled TRa pooled TRb and pBabe cells were allowed to proliferate for 48 h after which they were fixed and incubated in 40 mg/ml propidium iodide with 40 mg/ml ribonuclease and analysed for DNA content on a FACScan. As shown, expression of TRb1 significantly increased the percentage of resting cells (G0/ G1) and decreased the number of cells entering S phase to a similar extent. Results are the mean7s.e. (n ¼ 4) and are significant at a confidence level of Po0.05 (*) by Student's t-test cells showed no hyperphosphorylation of Rb until 24 h after stimulation. Since Rb phosphorylation is delayed in TR8b cells, a downregulation of D-type cyclin protein levels might be expected. To examine whether the expression patterns of these G1 proteins were altered by the action of TRb1, cells were rendered quiescent, serum stimulated, and Western blots for D-type cyclins were performed on total cell extracts. As shown (Figure 5b ), the induction dynamics of cyclins D1, D2, and D3 were markedly delayed in serum-stimulated TR8b cells compared to control pBabe cells. D-type cyclins were induced in response to mitogens as early as 8 h after serum stimulation in pBabe, whereas their levels remained low in TR8b, with control levels not being reached until 24 h. These results strongly correlate with the lack of Rb phosphorylation in these cells shown in Figure 5a . Cyclin E protein showed the same delayed time course as Rb phosphorylation and D-type cyclins induction. Since cyclin E is the regulatory subunit of Cdk2, we examined the activation state of Cdk2, which can be detected as a faster migrating band on a Western blot. As can be seen in Figure 5b , the activation time course of Cdk2 in TR8b fibroblasts followed the same pattern as the other G1/S progression molecules. To complete our analysis, we studied p27 Kip1 , the major G1-phase cell-cycle inhibitor, in these cells. p27
Kip1 exhibited higher levels in TR8b resting cells (G0) compared to Expression of G1/S progression molecules is altered in TRb1-expressing fibroblasts. Swiss 3T3-pBabe and TR8b cells were rendered quiescent and stimulated for the indicated times with T 3 / T 4 -depleted serum. Cell extracts were analysed by Western blot and probed with different antibodies recognising several G1/S progression molecules (cyclins D2, D3, E, Cdk2, and p27). Results show one representative experiment of three performed. The blots were probed with an anti-actin antibody. Quantifications of these blots were performed by scanning densitometry and showed that after 8 h, in pBabe cells cyclin D3 levels were induced more than twofold and cyclin E levels increased more than three-fold in response to mitogens, whereas in TRb1 cells their levels remained low until 24 h of serum exposure when they equalled the levels in control cells Figure 4 Expression of TRb1 lengthens the cell-cycle time. Cellcycle length was analysed by cumulative BrdU labeling. Briefly, 5 Â 10 4 cells/ml were seeded onto glass coverslips and refed the next morning with fresh T 3 /T 4 -depleted medium containing 10 mM BrdU. Coverslips were removed at indicated times, fixed, and stained with anti-BrdU antibody. Labeling index represents the ratio between the total cell number (determined by phase-contrast cell counting) and BrdU þ cells, and is plotted against time. Total cell-cycle time (T c ) and S-phase time (T s ) were calculated from the line of best fit, and are depicted graphically. Note that for cells expressing TRb1, cell-cycle length is 10 h longer than for pBabe cells. In contrast, S-phase times for both cell types were barely different. The asterisks indicate that the difference between the pairs denoted is significant at a confidence level of Po0.05 (*) or Po0.01 (**) by Student's t-test controls. Moreover, the kinetics of p27
Kip1 degradation upon serum stimulation was concomitantly slowed down in cells expressing TRb1. In G1, Cdk2 activity depends on its association with cyclin E, p27 Kip1 , and its phosphorylation state. Our results presented so farlower levels of cyclin E, higher levels of p27 Kip1 , and lack of Cdk2 phosphorylation -strongly suggested that in TR8b cells Cdk2 activity would be inhibited. To confirm this prediction, Cdk2 activity was analysed by in vitro kinase assays at the same time points (Figure 6 ). As expected, Cdk2 immunoprecipitates prepared from TR8b cells showed no activity (measured by histone H1 phosphorylation) up to 24 h after serum stimulation (Figure 6a) . Moreover, at 24 h Cdk2 activity remained 30% lower than in control cells. In agreement with this, a lack of activating phosphorylation of the kinase was observed when the immunoprecipitates were analysed by Western blot with Cdk2 antibodies (bottom panel). Finally, we assayed Cdk2 activity present in cyclin E immunoprecipitates ( Figure 6b ). We found that the kinase activity associated with cyclin E was also reduced in TR8b cells. These data indicate that TRb1 is responsible for sustained growth retardation through targeting of the G1 regulatory machinery.
TRb1 expression inhibits serum-induced E2F-1 transcriptional activity
The activation of the E2F transcription factor family after Rb phosphorylation is the key regulatory event in the G1/S transition. Since the expression of TRb1 impairs Rb phosphorylation (Figure 5a ), we wanted to examine E2F-1 transcriptional activity in the presence of this receptor by transfecting an E2F-1 reporter plasmid. However, the Swiss 3T3 cells used in this study showed such a low transfection efficiency that these experiments could not be performed. Hence, we used NIH-3T3 fibroblasts for this purpose. NIH-3T3 cells were transfected in serum-free conditions with a TRb1 expression vector together with a reporter plasmid containing three copies of the E2F-1-response element from the dihydrofolate-reductase gene (Figure 7 ). After transfection, the cells were stimulated with serum, harvested at 16 h, and assayed for luciferase and bgalactosidase activities. As expected, the endogenous transcriptional activity was increased by five-fold upon serum stimulation. Cotransfection of TRb1 dramatically downregulated E2F-1 transcriptional activity at this time point. The specificity of this effect was confirmed by transfection with a mutated inactive E2F-1 reporter. Inhibition of E2f-1 transcriptional activity caused by the transient transfection of TRb1 provides further evidence of the regulation of the G1/S transition by TRb1.
TRb1 inhibition of the E2F-1 activation in response to serum is ligand independent but requires a functional DNA-binding domain
To determine the participation of each of the different TRb1 domains in the observed inhibition of E2F-1 transcriptional activity, we used several TRb1 mutants Immunoprecipitation of cyclin E and in vitro kinase assay of the immunoprecipitates rendered similar results. Cyclin E-associated kinase activity was reduced at 16 and 24 h, as shown by the decrease found in histone H1 phosphorylation at these times TRb1 inhibits cell proliferation E Porlan et al (schematically depicted in Figure 8 ) in transient transfection experiments, as above. As shown, the construct bearing mutations that inactivate DNA binding (C127A) was able to abrogate the E2F-1 transcriptional blockade exerted by wild-type TRb1 (Figure 8 ). In contrast, the ligand-binding domain was not required for TRb1 action, as shown by transfection with the point-mutant G345R. In addition, mutations that block interactions with the nuclear corepressor NCoR (AHT) or that disable homodimerization did not change the effect observed with TRb1 wild type.
Discussion
In the present study, we demonstrate that TRb1 blocks 3T3 fibroblasts proliferation in a ligand-independent manner by decreasing cyclins D and E levels, Cdk2 activity and preventing phosphorylation of Rb accompanied by a significant repression of E2F-1 transcriptional activity. In our effort to study if the two major TRs (TRa1 and TRb1) play isoform-specific roles in cell proliferation, independently of cell differentiation, we selected Swiss 3T3 fibroblasts, a cell system widely used to analyse cell division and mitogen-stimulated cell proliferation (Rozengurt and Sinnett-Smith, 1983) . For that purpose, the low levels of functional TRs present in this cell line were increased by infection with retroviral constructs containing each isoform (Figure 1 and Table 1 ). Our most striking finding is that ligand-free TRb1 receptor is sufficient to provoke a drastic decrease of DNA synthesis (shown in Figure 2 ). In contrast, expression of the TRa isoform at the same level did not affect the proliferation rate of these cells. The elucidation of the bases for this isoform specificity will be worthy to pursue. It has been shown that the A/B domain of TRb2 mediates the interaction with a different set of coregulators, which in turn are able to elicit specific biological responses in the absence of the ligand (Oberste-Berghaus et al., 2000) . Hence, it is possible that the specificity of this action might be due to the ability of the b isoform to recruit and assemble particular coregulator complexes.
We established that the length of the cycle in TRb1-expressing cells increased from 30 to 40 h, with the same duration of the S phase (Figure 4) . This observation together with the strong reduction in DNA synthesis shown in Figure 2a and the data obtained by flow cytometry (Figure 3) suggested that the control points of the G1/S transition might be altered in TRb1 cells, and prompted us to examine the activation pattern of these molecules. Indeed, we show here that the levels and activity of G1/S main regulators after mitogenic induction of the cell cycle are markedly affected in TRb1 fibroblasts ( Figure 5 ). The induction of cyclins D after serum stimulation of resting cells was much delayed in TRb1 compared to control fibroblasts, taking place only at late time points. The same delay occurs in the phosphorylation of Rb. Since phosphorylation of Rb leads to E2F-1 transcription activation and cyclin E is a target of this transcription factor, we expected to find decreased levels of this cyclin. In agreement, TRb1 cells present a delayed increase in cyclin E levels and consistently fail to fully activate Cdk2 (Figure 6 ), supporting the idea that E2F-1-mediated transcriptional activation is affected by TRb1. In agreement, transient expression of this isoform represses the endogenous E2F-1 transcriptional activity induced by serum (Figure 7) . In this regard, very recently, T 3 has been implicated in the control of E2F-1 expression through a negative T 3 -response element (TRE) in its promoter (Nygard et al., 2003) . In this study, E2F-1 promoter activity was enhanced by the presence of unbound TRs and suffered a repression upon addition of the hormone. Although E2F-1 protein levels were not measured in this report, and assuming that they follow the same pattern as its mRNA, we would then expect higher levels of E2F-1 protein in TRb-or TRa-expressing cells as compared with the control. Regardless of the possible higher protein levels due to the unbound expression of the TRs, we demonstrate that transient expression of TRb1 represses the endogenous E2F-1 transcriptional activity induced by serum. Our results are consistent with the hypothesis that TRb decreases the activity of G1 cell-cycle regulators including Rb, thus preventing the activation of the endogenous E2F-1 in response to serum. Hence, our and Nygard's results suggest that both expression and activity of E2F-1 are regulated by TR/T 3 . E2F-1 activation is inhibited by TRb1 through the possible regulation of the key molecules directly involved in the activation of this transcription factor, and in addition, its expression is repressed by T 3 through a negative TRE present in its promoter region. E2F expression/activation might serve as paradigm to illustrate how T 3 and its receptor could act reinforcing each other to control cell differentiation with its concomitant growth arrest. The lack of effect of T 3 on fibroblasts proliferation suggests that T 3 -mediated growth arrest is linked to its control of cell differentiation. In accordance with this hypothesis, in neuroblastoma cells and oligodendrocyte precursors, it has been shown that T 3 , through the TRb1 isoform, induces cell proliferation withdrawal and differentiation (Durand et al., 1997; Perez-Juste and Aranda, 1999; Tokumoto et al., 2002) . In the light of our results, it is tempting to speculate that T 3 binding builds up the effect on cell cycle already carried out by the unbound receptor and together with the induction of the cell-specific gene expression pattern leads to cell differentiation. In this context, other ligands of the nuclear receptor superfamily have been shown to control proliferation of target tissues through a similar mechanism. Whether some of the receptors for these ligands behave as TRb1 will be an interesting subject to investigate in the future.
Finally, our findings also indicate that the TRb1-mediated inhibition of E2F-1 transcriptional activity we describe does not require hormone binding, being ligand independent (Figure 8 ). The TRb1 point-mutant G345R, which is unable to bind T 3 , is as good repressor as wild-type TRb1. Moreover, transfections with the TRb1 mutants AHT and R429Q (Hayashi et al., 1994; Yen et al., 1995; Baumann et al., 2001 ) also indicate that functional interaction with the nuclear corepressor NCoR and homodimerization are not required. Only a functional DNA-binding domain appeared to be essential for the action of the TRb1 receptor on E2F-1 activation. We cannot conclude from the present data that transcriptional regulation is the mechanism mediating this effect. Interestingly, it has been shown that hTRb1 physically and functionally interacts with p53 in the cell (Yap et al., 1996) and that this interaction is mediated by the DNA-binding domain of TR and several domains of p53 (Qi et al., 1997) . As result of this interaction, on the one hand, p53 blocks TR constitutive activation but not ligand-dependent stimulation of gene expression and, on the other, TRb1 leads to an inhibition of some p53-regulated genes (Barrera-Hernandez et al., 1998).
Our findings suggest that TRb1 might be a key molecule in the control of T 3 growth arrest associated with differentiation during development. Under certain pathological circumstances where cell cycle is deregulated, TRb1 may also be critical for proliferation suppression. In this regard, a mouse model of thyroid carcinogenesis has been generated by the introduction of a dominant-negative mutant of the TRb1 gene (Suzuki et al., 2002) . Also, it has been reported that there is loss or substantial reduction of TRb transcripts in samples of colon carcinoma (Markowitz et al., 1989) , supporting a possible link between TRb and different neoplasias. It is also tempting to speculate that mutant TRbs from patients with resistance to thyroid hormone would be able to block cell-cycle progression even in the presence T 3 by virtue of dominant-negative activity (see for a review Yen, 2003) . In conclusion, we have revealed a novel antiproliferative biological effect of TRb1 that TRb1 inhibits cell proliferation E Porlan et al may be crucial for the processes governing cell proliferation in development and cancer.
Materials and methods
Cell culture and transfection
Mouse retroviral packing cells and Swiss 3T3 cells were grown at 371C in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and kept in an humidified atmosphere at 5 and 10% CO 2 , respectively. For the expression of the TRs, infected Swiss 3T3 cells were grown in medium containing FBS previously treated with the ion exchange resin AG1-X8 to deplete it from T 3 and T 4 (tetraiodothyronine) (Samuels et al., 1979) . Swiss 3T3 fibroblasts were seeded at low density (5 Â 10 4 cells/ml) and split every 3 days to avoid loss of contact inhibition and transformation. For G0 synchronization experiments, cells were seeded at low density and allowed to reach confluence for 5 days (to ensure contact inhibition arrest), followed by serum deprivation for another 48 h after which cells were induced to enter S phase by refeeding. For transfection experiments mouse NIH-3T3 fibroblasts were used and maintained as above at 5% CO 2 . Reporter plasmids containing three copies of the E2F-1-response element (wild-type or point mutated inactive) from the dihydrofolate-reductase gene driving the transcription of the luciferase gene (Campanero et al., 2000) were used along with vectors either empty (Clontech, Palo Alto, CA, USA) or containing TRa, wild-type TRb or several TRb point mutants (Hayashi et al., 1994; Yen et al., 1995; Baumann et al., 2001) . All transfections included 0.5 mg of pCMV-b-galactosidase (Clontech) to test transfection efficiency. NIH-3T3 cells were seeded at a density of 10 5 cells/ml and allowed to attach overnight followed by starvation in serum-free medium for 6 h. After this period of time, cells were transfected overnight using JetPei cationic polymer transfection reagent (Poly Plus Transfection, Illkirch, France) or Lipofectamine 2000 (Invitrogen, UK), before being stimulated with T 3 /T 4 -depleted FBS. Cell extracts were obtained at different times and assayed for luciferase activity with a Luciferase Reporter Gene Assay (Roche Molecular Biochemicals) as well as for b-galactosidase activity, used for normalization of luciferase values.
Retroviral infection of Swiss 3T3 fibroblasts, RT-PCR analysis, and identification of positive clones by T 3 binding assay
For infections, Gp þ E-86 cells were seeded at 5 Â 10 4 cells/ml and transfected using calcium phosphate with the retroviral vector pBabe (Morgenstern and Land, 1990) or the same vector containing the chick-TRa1 (TRa) or the human-TRb1 (TRb) cDNAs. The day after transfection, cells were selected by adding puromycin (2.5 mg/ml; Sigma). Resistant cells were used for the infection of Swiss 3T3 fibroblasts by coculturing both cell types: 8 Â 10 4 GP þ E-86 cells of each genotype (pBabe, TRa and TRb) were plated on different inserts and 2 Â 10 4 Swiss 3T3 cells were seeded onto six-well plates. Cells were grown separately for the first 24 h after which the inserts were placed into the wells, refed, and kept in culture for another 24-48 h to allow the retroviral particles in the supernatant of the GP þ E-86 packaging cells to infect the Swiss 3T3 fibroblasts. After infection, the inserts were removed and fibroblasts were selected in puromycin-containing medium (2.5 mg/ml). Resistant colonies were either pooled or isolated as single clones. Pools were characterized (tested for the retroviral expression of the TR genes) by RT-PCR. For this purpose, total RNA was isolated from cells lysed in guanidium isothiocyanate as described (Chomczynski and Sacchi, 1987) . RNA (2 mg) was reverse transcribed for 1 h at 421C using 200 U of Moloney murine leukemia virus reverse transcriptase (Promega). Reactions were performed at standard conditions using Pfx DNA polymerase (Invitrogen, UK) following the manufacturer's instructions. The detection of cTRa1 and hTRb1 transcripts was carried out using specific pairs of sense and antisense oligonucleotides: TRa1-sense, 5 0 -CAC ACC ACG CAC TGT TCA TCT T-3 0 ; TRa1-antisense, 5 0 -CAC ACC ACG CCA CTG TTC ATC TT-3 0 ; TRb-sense, 5 0 -GGA TGA GAT GTG GCG ACG ACT G-3 0 ; TRb-antisense, 5 0 -CGG GAT CCA CCA TGA CAG AAA ATG GCC TTA-3 0 . In all, 12 clones of each genotype were obtained (pBabe, TRa and TRb) among which only those showing the highest T 3 /T 4 binding capacity determined as described (Pastor et al., 1994) were used in this study.
Measurement of cell number and DNA synthesis assays
For proliferation assays, cells were seeded at low density (5 Â 10 4 /ml) in T 3 /T 4 -depleted medium and cell number in culture was determined by the Crystal Violet method. Briefly, 35-mm triplicates for each time point were washed and fixed for 15 min in 1% glutaraldehyde. Following fixation, the dishes were washed and stained with 0.1% crystal violet (Merck) for 15 min. After removing the dye, the plates were washed and air-dried prior to solubilization in 10% acetic acid and measurement of the optical density at 595 nm (cell number correlates linearly with OD 595 ). For DNA synthesis assays, proliferative cultures of Swiss 3T3 cells were washed twice and incubated with medium containing [ 3 H]thymidine (0.2 mCi/ml, 1 mM) at indicated time points. After 3 h of incubation at 371C, cultures were washed twice with phosphate-buffered saline and incubated in 5% trichloroacetic acid at 41C for 20 min to remove acid-soluble radioactivity, washed with ethanol, and solubilized in 1 ml of 0.1 M NaOH and 0.1% SDS. The acidinsoluble radioactivity was determined by scintillation counting in 6 ml of Beckman Readysafe.
Fluorescence-activated cell sorter (FACS)
3T3 pBabe, pooled TRa, and pooled TRb cells were seeded at low density and allowed to proliferate for 48 h after which they were trypsinized, washed with phosphate-buffered saline, and fixed in cold 70% ethanol. Cells were resuspended in phosphate-buffered saline containing 40 mg/ml propidium iodide and 40 mg/ml ribonuclease, and incubated at 371C for 45 min. Four samples of each cell type were analysed for DNA content with a Becton Dickinson and Co. (Franklin Lanes, NJ, USA) FACScan using Cell Quest software.
BrdU labeling and cell-cycle analysis
For BrdU labeling cells were seeded at low density on glass coverslips and refed next morning with fresh medium containing 10 mM BrdU. Coverslips were then removed at various times, fixed, and stained with anti-BrdU antibody following the instructions provided by the manufacturer (Roche Molecular Biochemicals). Cell-cycle analysis was performed considering that a normal constantly cycling cell population has a labeling index (determined by the fraction of BrdU þ cells) that increases in a linear manner with time until all cells are labeled (labeling index ¼ 1). By plotting the labeling index versus time of BrdU exposure, the total cell-cycle time (T c ) and S phase time (T s ) can be deduced by the formulae T c ¼ 1/m and T s ¼ n/m, where m is the gradient and n is the intercept on the y-axis (Durand and Raff, 2000) . The line of best fit for m and n was calculated by the method of least squares. Each cumulative experiment was repeated twice with similar results. One representative experiment is shown.
Western blot analysis, immunoprecipitation, and kinase activity assays
For Western blotting purposes, cell monolayers were washed twice in ice-cold phosphate-buffered saline and lysed for 30 min on ice in lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 1 mM 1,4-dithio-DL-threitol), which included protease and phosphatase inhibitors (1 mM NaF, 0.5 mM Na 3 VO 4 , 100 mg/ml phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin, 5 mg/ml leupeptin, 1 mM b-glycerophosphate, 5 mM PP i Na). Lysate supernatants were collected after sedimentation of cellular debris by centrifugation (10 min at 14 000 r.p.m.). Protein concentration was determined using the BCA Protein Assay from Pierce. Equal amounts of total protein (50 mg) were resolved by SDS-PAGE, transferred to nitrocellulose membranes (Schleider & Schuell), blocked with 5% skimmed milk powder in 10 mM Tris, 150 mM NaCl, 0.05% Tween-20, and probed with the following primary antibodies: cyclin D1,2 (M-20), cyclin D3 (C-16), cyclin E (M-2), Cdk 2 (M2), p27 Kip1 (C-19) all from Santa Cruz Biotechnology Inc.; TRa and TRb1 antibodies kindly provided by Dr LL Sarlie`ve were raised against the peptides corresponding to the residues 12-33 of the N-terminal region of the TRa receptor, and the residues 71-85 of the N-terminal region of the TRb1 receptor (Carre et al., 1998) ; pRb (G3-245) was from Pharmingen, San Diego CA, USA. Immunoreactive bands were visualized using horseradish peroxidase-conjugated IgG (Amersham Pharmacia Biotech.) and subsequent enhanced chemiluminescence detection (Perkin-Elmer Life Sciences Inc., MA, USA). For immunoprecipitation assays, cells were lysed and protein extracts were obtained and quantified as above. Equal amounts (800 mg) of total protein were incubated with 1 mg of the appropriate antibody (cyclin E or Cdk2) and Protein A-Sepharose beads (Amersham Pharmacia Biotech.) for 3 h at 41C, washed twice with lysis buffer, centrifuged, and resolved by SDS-PAGE, followed by immunoblot analysis as described. For in vitro kinase assays, immunoprecipitates were washed twice more with lysis buffer without Triton X-100 and twice with kinase buffer (50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 1 mM 1, 4-dithio-DL-threitol). Reactions were performed in 10 ml of kinase buffer containing 15 mg histone H1 (Roche), 0.3 mM ATP, and 0.5 mCi [ 32 P]ATP (Amersham Pharmacia Biotech.), for 10 min at 301C. Reactions were stopped by adding an equal volume of 2 Â SDS-PAGE sample buffer (1 M Tris-HCl, pH 6.8, 6% SDS, 4% 2-mercaptoethanol, and 10% glycerol). Radiolabeled histone H1 was resolved by SDS-PAGE and the autoradiograms were quantified using densitometry analysis software (NIH Image).
Abbreviations T 3 , triiodothyronine; T 4 , tetraiodothyronine; TR, thyroid hormone nuclear receptor; TRa1, thyroid hormone receptora1; TRb1, thyroid hormone receptor-b1; Cdk, cyclin-dependent kinase; Cki, cyclin-dependent kinase inhibitor; Rb, retinoblastoma susceptibility protein; BrdU, 5-bromo-2 0 -deoxyuridine.
